CBD Legality in India: What the Law Actually Says in 2026

India does not have a single law that says “CBD is legal” or “CBD is illegal.” Instead, CBD’s legal status depends on where it comes from on the plant, how it is sold, and which government body is regulating that particular product. This guide breaks down the three separate legal pathways that currently apply, so you can understand what is actually permitted before buying, importing, or selling CBD in India.

Disclaimer: This article is for educational purposes only and is not legal or medical advice. Laws referenced here can change, and enforcement can vary by state. Consult a qualified Indian lawyer or your local Narcotics Control Bureau office before making sourcing, import, or retail decisions involving cannabis-derived products.

Key Takeaways

• India has no single “CBD law.” Legality depends on which part of the cannabis plant a product is derived from and which regulator (Ayush, FSSAI, or state excise) governs its sale.
• The Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985 controls charas (resin) and ganja (flowering or fruiting tops). It excludes cannabis seeds and leaves when not accompanied by the tops.
• Ayush-licensed CBD products, typically sold as Ayurvedic formulations under the Drugs and Cosmetics Act, 1940, represent the clearest legal retail pathway.
• FSSAI permits hemp seed, hemp seed oil, and hemp seed flour as food, with cannabidiol capped at 75 mg/kg and no health or therapeutic claims allowed on the label.
• A small number of states, led by Uttarakhand, license industrial hemp cultivation for fibre and seed under Section 10 and Section 14 of the NDPS Act.
• General retail CBD oils and isolates sold outside the Ayush or FSSAI frameworks, particularly imported full-spectrum products, sit in an unregulated gray zone with real compliance risk.

Current Legal Status at a Glance

This table summarizes how different CBD-related product categories are currently treated.

Product Category	Legal Status	Governing Framework
Charas (cannabis resin) and ganja (flowering/fruiting tops)	Prohibited	NDPS Act, 1985, Section 2(iii)
CBD sold as a licensed Ayurvedic medicine (e.g., Vijaya-based formulations)	Legal, license-dependent	Drugs and Cosmetics Act, 1940 plus Ministry of Ayush licensing
Hemp seed, hemp seed oil, hemp seed flour sold as food	Legal, subject to composition limits	FSSAI Food Products Standards and Food Additives Fifth Amendment Regulations, 2021
Industrial hemp cultivation for fibre and seed	Legal only under state license	NDPS Act Sections 10 and 14, plus state excise policy (currently Uttarakhand)
Bhang (leaf-based preparation)	Legal in states that permit it, taxed as an intoxicant	State excise law; excluded from the NDPS Act’s cannabis definition
General retail CBD oil, tinctures, or isolate outside Ayush or FSSAI channels	Unregulated gray area	No dedicated framework; import and sale carry compliance risk

The Legal Foundation: How the NDPS Act Defines Cannabis

Every legal pathway for CBD in India traces back to a single definition in India’s central narcotics statute. Section 2(iii) of the Narcotic Drugs and Psychotropic Substances Act, 1985 defines “cannabis (hemp)” as charas (separated resin), ganja (the flowering or fruiting tops, excluding seeds and leaves when not attached to those tops), and any mixture or drink prepared from either. Critically, the statutory definition does not include cannabis seeds or leaves when they are separated from the flowering tops.

This exclusion is the legal hinge point for the entire hemp and CBD industry in India. Because seeds and leaves fall outside the NDPS Act’s definition of prohibited cannabis, products legitimately derived from those plant parts can be regulated under ordinary food, drug, or agricultural law instead of narcotics law. That is also why bhang, a leaf-based preparation, is treated separately from ganja and charas and regulated instead through state excise departments.

Two other NDPS Act provisions matter for hemp specifically. Section 10 gives state governments the power to license cultivation of cannabis for medical, scientific, or industrial purposes. Section 14 allows the government to permit cultivation exclusively for horticultural or industrial use, including low-THC cultivar research. These two sections are what allow individual states to run their own hemp cultivation licensing programs, discussed further below.

Pathway One: Ayush-Licensed CBD as Ayurvedic Medicine

The most established legal retail route for CBD in India runs through the Ministry of Ayush. Cannabis leaf extract, including CBD-rich formulations often marketed under the classical name Vijaya, can be manufactured and sold as an Ayurvedic proprietary medicine when the manufacturer holds a valid license under the Drugs and Cosmetics Act, 1940. Because the raw material is sourced from leaves rather than flowering tops, it falls outside the NDPS Act’s cannabis definition, while the finished product is regulated as a scheduled Ayurvedic drug requiring a license to manufacture and, typically, sale under practitioner guidance.

For a brand or consumer, the practical marker of legitimacy in this pathway is the presence of a valid Ayush manufacturing license number on the product packaging, along with sourcing documentation showing the extract came from leaf material rather than flowering tops or resin. Products lacking this licensing, even if labeled “Ayurvedic,” should be treated with caution.

Pathway Two: FSSAI-Regulated Hemp Seed Foods

Separately from the Ayush pathway, the Food Safety and Standards Authority of India created a dedicated food category for hemp seed products. Through the Food Safety and Standards (Food Products Standards and Food Additives) Fifth Amendment Regulations, 2021, FSSAI now permits hemp seed, hemp seed oil, and hemp seed flour to be sold as food or used as a food ingredient, provided the products meet defined composition standards.

Under this standard, cannabidiol content in any hemp seed food product cannot exceed 75 mg/kg, and cannabinoids may only be present as natural residue on the seed itself, not as an added extract. THC levels are also capped. Labeling requirements are strict: packaging cannot reference cannabis or marijuana by name, cannot depict any part of the plant other than the seed, and cannot carry any wellness, nutrient, or therapeutic claim tied to CBD content. Products intended for infants under 24 months are barred outright. Cultivation of the source plant must still comply with the NDPS Act and any applicable state licensing.

Pathway Three: State-Licensed Industrial Hemp Cultivation

Because cannabis cultivation licensing sits with individual states under Section 10 of the NDPS Act, hemp farming legality varies by state. Uttarakhand became the first Indian state to license industrial hemp cultivation, issuing its first pilot license in 2018 for fibre production, and it remains the most established hemp-growing state. The state’s Excise Department, working with the Centre for Aromatic Plants in Selaqui, Dehradun as the nodal testing agency, licenses farmers and companies to cultivate hemp cultivars with THC content below 0.3 percent. Applicants apply through the District Magistrate’s office and must show land ownership, a clean legal record, and no duplicate licensing elsewhere.

Other states, including Himachal Pradesh, Madhya Pradesh, and Uttar Pradesh, have explored or piloted their own hemp cultivation frameworks, but licensing infrastructure and enforcement consistency remain far less developed than in Uttarakhand. Anyone considering hemp cultivation in a state outside Uttarakhand should confirm current status directly with that state’s excise department, since these programs are early-stage and subject to change.

What Remains a Gray Area or Restricted

Several categories of CBD products commonly sold online do not fit neatly into any of the three pathways above, and buyers should understand the added risk involved.

• Imported full-spectrum CBD oil or isolate sold as a general wellness product (not as a licensed Ayurvedic medicine and not as an FSSAI-compliant hemp seed food) has no dedicated legal framework in India. Sellers in this category are not clearly authorized, and import or sale can expose both buyer and seller to scrutiny under the NDPS Act, Customs Act, or Drugs and Cosmetics Act.
• Any THC content above trace, naturally occurring seed residue pushes a product back toward the NDPS Act’s restricted definition, regardless of how it is marketed.
• CBD edibles or gummies that are not manufactured under an FSSAI food license or an Ayush drug license occupy the same unregulated space as general retail oils.
• Recreational cannabis products, including ganja, charas, and any THC-containing edible, remain illegal nationwide regardless of wellness framing, and enforcement is active even in states with informal tourist markets.

Compliance Considerations for Consumers and Brands

• Check packaging for either an Ayush manufacturing license number or an FSSAI license number before purchase; a product with neither has no clear legal basis.
• Request a certificate of analysis confirming THC content and, for food products, confirming CBD content stays within the FSSAI 75 mg/kg limit.
• Avoid products or listings that make therapeutic or medical claims, since these can trigger both drug-labeling violations and NDPS scrutiny.
• For cultivation or manufacturing ventures, confirm state-level licensing status directly with the relevant excise department rather than relying on marketing claims from equipment or seed suppliers.
• Treat Delta-9 THC products as an entirely separate legal category from CBD; they carry materially higher legal risk and are not addressed by the pathways above.

Conclusion

CBD in India is legal, but only within specific, license-dependent lanes rather than as a broadly deregulated retail category. The clearest paths run through Ayush-licensed Ayurvedic formulations and FSSAI-compliant hemp seed foods, both of which rely on the same statutory exclusion of cannabis seeds and leaves from the NDPS Act’s definition of prohibited cannabis. Outside those lanes, particularly for imported full-spectrum oils and unlicensed edibles, the legal footing is considerably less certain. Anyone buying, importing, or selling CBD in India should verify licensing status directly rather than relying on a seller’s claims.

Final Answer

Yes, CBD is legal in India, but only when sold as a licensed Ayush Ayurvedic product or as an FSSAI-compliant hemp seed food within the 75 mg/kg CBD limit. General retail CBD oil sold outside these two frameworks does not currently have clear legal standing.

Frequently Asked Questions

---

Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. The statements in this article have not been evaluated by any regulatory health authority. Always consult with a healthcare professional before making decisions about wellness products.

Legal Disclaimer: Legal status varies by product category, state, and licensing status, and can change without notice. This information is general in nature and does not constitute legal advice. Always verify current regulations with a qualified professional or the relevant Indian regulatory authority before making purchasing, cultivation, import, or sale decisions.

Sources

1. Narcotic Drugs and Psychotropic Substances Act, 1985, Section 2, India Code (Government of India). indiacode.nic.in
2. Narcotic Drugs and Psychotropic Substances Act, 1985, full text and rules, Government of India. upload.indiacode.nic.in
3. Food Safety and Standards (Food Products Standards and Food Additives) Fifth Amendment Regulations, 2021, Food Safety and Standards Authority of India (FSSAI), notified 15 November 2021.
4. Drugs and Cosmetics Act, 1940, Government of India (governing Ayush-licensed Ayurvedic proprietary medicines).
5. Government of Uttarakhand, Excise Department order authorizing industrial hemp cultivation licensing, letter no. 581/XXIII/2018/04(11)/2012, dated 29 May 2018.
6. Government of Uttarakhand, nodal agency designation for industrial hemp testing, order no. 984/XVI-2/19/19(23)/2019, dated 30 December 2019.